Disease Management for Coronary Artery Patients

Not Applicable

Completed

• Conditions: Patient Empowerment; Coronary Artery Disease

• Registration Number: NCT04556006
• Lead Sponsor: Kilis 7 Aralik University

Brief Summary

This randomized controlled trial was conducted with 58 patients hospitalized in the cardiology clinic of a state hospital. Personal Information Form, Anthropometric measurements, Framingham risk score, and compliance questionnaire (CQ) were used to collect the data.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-01
• Primary Completion: 2019-12-30
• Study Completion: 2020-03-30
• Study First Submitted: 2020-09-03
• Study First Submitted QC: 2020-09-14
• Study First Posted: 2020-09-21
• Results First Submitted: 2023-10-09
• Status Verified: 2024-03
• Results First Submitted QC: 2024-03-28
• Last Update Submitted: 2024-03-28
• Results First Posted: 2024-08-21
• Last Update Posted: 2024-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• aged 18 and over,
• diagnosed with coronary artery disease for at least 2 months,
• no hearing and vision problem,
• no perception and expression deficiency,
• not diagnosed with any psychiatric disease,
• living in Kilis province,
• voluntary to participate in the study.

Exclusion Criteria

• aged 18 under,
• diagnosed without coronary artery disease for at least 2 months,
• hearing and vision problem,
• perception and expression deficiency,
• diagnosed with any psychiatric disease,
• no living in Kilis province,
• no voluntary to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Compliance Questionnaire Scores of the Participants	Initially-12 weeks	Compliance Questionnaire is a form allowing to investigate 11 different areas such as the use of medication causing maladaptation in disease management in individuals with chronic illnesses, diet, weight loss, limiting physical activity, exercise, coping with stress, alcohol use, smoking, sexual activity problems, caffeine intake and working/job life. In the form allowing Likert-type evaluation, the participant is expected to select one of the options 0 (never), 1 (very rarely), 2 (sometimes), 3 (most of the time) or 4 (always) while expressing his/her compliance level for each adaptation area. The scores corresponding to the given expression are summed and Compliance Questionnaire score for each participant is determined. The score range that can be obtained for each subscale is 0-4. The Compliance Questionnaire total scores is between 0-44. High scores mean a better as it an increase in the compliance level to the disease.

Trial Locations

Locations (1)

Kilis 7 Aralık University; 🇹🇷 Kilis, Turkey